-
Innovation Ranking
NewInnovation Ranking – Blueprint Medicines Corp
Blueprint Medicines Corp (Blueprint Medicines), formerly Hoyle Pharmaceuticals Inc, is precision therapy company that inventing medicines for people with cancer and blood disorders. The company product pipeline includes AYVAKIT (avapritinib) medicine to treat gastrointestinal stromal tumor (GIST) and GAVRETO (pralsetinib) against non-small cell lung cancer in adults, BLU-263 targeting indolent systemic mastocytosis. It also offer GAVRETO, BLU-701, BLU-945, BLU-451, BLU-222 and BLU-852. Blueprint Medicines is advancing pralsetinib inhibitor against RET (Ret Proto-Oncogene) modified medullary thyroid carcinoma and other solid tumors...
-
Company Insights
Innovation and Patenting activity of Blueprint Medicines Corp Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Blueprint Medicines Corp Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewNet Present Value Model: Novartis AG’s Peptide to Antagonize GRPR for Oncology
Empower your strategies with our Net Present Value Model: Novartis AG's Peptide to Antagonize GRPR for Oncology report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Vertex Pharmaceuticals Inc’s VX-548
Empower your strategies with our Net Present Value Model: Vertex Pharmaceuticals Inc's VX-548 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Sector Analysis
Thailand Renewable Energy Policy Handbook, 2024 Update
"Thailand Renewable Energy Policy Handbook 2024” is among the latest country specific policy reports from GlobalData, the industry analysis specialist. The report offers comprehensive information on major policies governing the renewable energy market in the country and provides information on renewable policies/developments at a regional/municipal level. The report discusses renewable energy targets and plans along with the present policy framework, giving a fair idea of overall growth potential of the renewable energy industry. The report also provides major technology specific...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BI-1206 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BI-1206 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BI-1206 in Solid Tumor Drug Details: BI-1206 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Avapritinib in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Avapritinib in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Avapritinib in Breast Cancer Drug Details: Avapritinib (Ayvakit, Ayvakyt) is an anti-neoplastic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pralsetinib in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pralsetinib in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pralsetinib in Solid Tumor Drug Details: Pralsetinib (Gavreto) is an anticancer...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMPT-314 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMPT-314 in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMPT-314 in Follicular Lymphoma Drug Details: IMPT-314 is under investigation for the...
-
Product Insights
Hypersecretory Conditions – Drugs In Development, 2023
Global Markets Direct’s, ‘Hypersecretory Conditions - Drugs In Development, 2023’, provides an overview of the Hypersecretory Conditions pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hypersecretory Conditions, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...